Want to see LUNG full AI Analyst Report?
LUNG Stock Chart & Stats
$1.17
-$0.05(-4.10%)
At close: 4:00 PM EDT
$1.17
-$0.05(-4.10%)
Day’s Range― - ―
52-Week Range$1.13 - $2.89
Previous CloseN/A
Volume238.62K
Average Volume (3M)454.13K
Market Cap
$97.06M
Enterprise Value$55.32
Total Cash (Recent Filing)$55.84M
Total Debt (Recent Filing)$56.21M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 04, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding42,948,270
10 Day Avg. Volume218,977
30 Day Avg. Volume454,128
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside199.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.04
Revenue Forecast (FY)$90.54M
Bulls Say, Bears Say
Bulls Say
Improving Gross Margin And Operating EfficiencyThe high gross margin and lower operating costs show improving unit economics and expense discipline. Narrower losses reduce the scale needed for break-even, while management expects roughly 76% gross margin for 2026, suggesting the improvement may persist.
Improved Liquidity And Extended Debt MaturityA larger liquidity runway and debt maturity extension reduce near-term refinancing pressure. Lower projected cash burn also improves financial flexibility, giving management more time to scale treating centers and pursue growth before needing additional capital.
Broader Commercial And International AdoptionExpansion of U.S. treating centers and growth outside China support a broader procedural footprint for Zephyr. Renewed Chinese registration preserves a future channel for international expansion, reducing reliance on any single market over time.
Bears Say
Persistent Losses And Negative Cash GenerationThe business still converts operating activity into substantial cash burn, requiring external funding or balance-sheet capacity. Although losses are narrowing, continued negative cash generation limits investment flexibility and raises execution risk until sustainable profitability is achieved.
Revenue Contraction And Delayed China RecoveryRevenue contraction indicates that commercial adoption has not yet produced consistent growth. The delayed China recovery removes an important source of potential demand for several quarters, increasing dependence on U.S. execution and other international markets.
Rising Leverage And Shrinking Equity CushionHigher leverage combined with a smaller equity base reduces the buffer available to absorb continued losses. If the return to growth or profitability is delayed, Pulmonx may face tighter financing options and greater dependence on additional capital.
Pulmonx News
LUNG FAQ
What was Pulmonx Corporation’s price range in the past 12 months?
Pulmonx Corporation lowest stock price was $1.13 and its highest was $2.89 in the past 12 months.
What is Pulmonx Corporation’s market cap?
Pulmonx Corporation’s market cap is $97.06M.
When is Pulmonx Corporation’s upcoming earnings report date?
Pulmonx Corporation’s upcoming earnings report date is Nov 04, 2026 which is in 73 days.
How were Pulmonx Corporation’s earnings last quarter?
Pulmonx Corporation released its earnings results on Jul 29, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.04.
Is Pulmonx Corporation overvalued?
According to Wall Street analysts Pulmonx Corporation’s price is currently Undervalued.
Does Pulmonx Corporation pay dividends?
Pulmonx Corporation does not currently pay dividends.
What is Pulmonx Corporation’s EPS estimate?
Pulmonx Corporation’s EPS estimate is -0.26.
How many shares outstanding does Pulmonx Corporation have?
Pulmonx Corporation has 42,948,270 shares outstanding.
What happened to Pulmonx Corporation’s price movement after its last earnings report?
Pulmonx Corporation reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 28.8%.
Which hedge fund is a major shareholder of Pulmonx Corporation?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (199.15% Upside)
$3.50 (199.15% Upside)
Blogger Sentiment
Bearish
LUNG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 112.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.05%
Trailing 12-Months
Company Description
Pulmonx Corporation
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
LUNG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic picture: multiple operational and financial improvements (notably a nearly 40% reduction in adjusted EBITDA loss, 16% YoY reduction in operating expenses, gross margin expansion, China registration renewal, filled U.S. leadership roles, and reiterated full-year guidance) signal meaningful progress on execution and financial leverage. Near-term challenges remain, including an overall revenue decline driven by the China shipment suspension, ongoing quarterly losses and cash burn, typical seasonality (Q3), and the multi-quarter ramp required for new sales hires and clinical enrollment timelines. On balance, the positive operational and balance-sheet developments outweigh the near-term headwinds, but material execution is still required to convert momentum into sustained revenue growth.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$3.50
▲(199.15% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
13.82% Insiders
16.67% Mutual Funds
28.80% Other Institutional Investors
36.63% Public Companies and
Individual Investors